133 related articles for article (PubMed ID: 16180905)
1. Structure-based approaches to improve selectivity: CDK2-GSK3beta binding site analysis.
Vulpetti A; Crivori P; Cameron A; Bertrand J; Brasca MG; D'Alessio R; Pevarello P
J Chem Inf Model; 2005; 45(5):1282-90. PubMed ID: 16180905
[TBL] [Abstract][Full Text] [Related]
2. A flexible-protein molecular docking study of the binding of ruthenium complex compounds to PIM1, GSK-3β, and CDK2/Cyclin A protein kinases.
Liu Y; Agrawal NJ; Radhakrishnan R
J Mol Model; 2013 Jan; 19(1):371-82. PubMed ID: 22926267
[TBL] [Abstract][Full Text] [Related]
3. Theoretical studies on the selective mechanisms of GSK3β and CDK2 by molecular dynamics simulations and free energy calculations.
Zhao S; Zhu J; Xu L; Jin J
Chem Biol Drug Des; 2017 Jun; 89(6):846-855. PubMed ID: 27863047
[TBL] [Abstract][Full Text] [Related]
4. Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2.
Lesuisse D; Dutruc-Rosset G; Tiraboschi G; Dreyer MK; Maignan S; Chevalier A; Halley F; Bertrand P; Burgevin MC; Quarteronet D; Rooney T
Bioorg Med Chem Lett; 2010 Mar; 20(6):1985-9. PubMed ID: 20167481
[TBL] [Abstract][Full Text] [Related]
5. Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2.
Li Y; Zhang J; Gao W; Zhang L; Pan Y; Zhang S; Wang Y
Int J Mol Sci; 2015 Apr; 16(5):9314-40. PubMed ID: 25918937
[TBL] [Abstract][Full Text] [Related]
6. Structural features underlying selective inhibition of GSK3β by dibromocantharelline: implications for rational drug design.
Zhang N; Zhong R; Yan H; Jiang Y
Chem Biol Drug Des; 2011 Mar; 77(3):199-205. PubMed ID: 21244636
[TBL] [Abstract][Full Text] [Related]
7. Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.
Deng Y; Shipps GW; Zhao L; Siddiqui MA; Popovici-Muller J; Curran PJ; Duca JS; Hruza AW; Fischmann TO; Madison VS; Zhang R; McNemar CW; Mayhood TW; Syto R; Annis A; Kirschmeier P; Lees EM; Parry DA; Windsor WT
Bioorg Med Chem Lett; 2014 Jan; 24(1):199-203. PubMed ID: 24332088
[TBL] [Abstract][Full Text] [Related]
8. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.
Talapati SR; Nataraj V; Pothuganti M; Gore S; Ramachandra M; Antony T; More SS; Krishnamurthy NR
Acta Crystallogr F Struct Biol Commun; 2020 Aug; 76(Pt 8):350-356. PubMed ID: 32744246
[TBL] [Abstract][Full Text] [Related]
9. Briefly bound to activate: transient binding of a second catalytic magnesium activates the structure and dynamics of CDK2 kinase for catalysis.
Bao ZQ; Jacobsen DM; Young MA
Structure; 2011 May; 19(5):675-90. PubMed ID: 21565702
[TBL] [Abstract][Full Text] [Related]
10. Type II Inhibitors Targeting CDK2.
Alexander LT; Möbitz H; Drueckes P; Savitsky P; Fedorov O; Elkins JM; Deane CM; Cowan-Jacob SW; Knapp S
ACS Chem Biol; 2015 Sep; 10(9):2116-25. PubMed ID: 26158339
[TBL] [Abstract][Full Text] [Related]
11. Identification and Characterization of an Irreversible Inhibitor of CDK2.
Anscombe E; Meschini E; Mora-Vidal R; Martin MP; Staunton D; Geitmann M; Danielson UH; Stanley WA; Wang LZ; Reuillon T; Golding BT; Cano C; Newell DR; Noble ME; Wedge SR; Endicott JA; Griffin RJ
Chem Biol; 2015 Sep; 22(9):1159-64. PubMed ID: 26320860
[TBL] [Abstract][Full Text] [Related]
12. Structural basis for the complete loss of GSK3beta catalytic activity due to R96 mutation investigated by molecular dynamics study.
Zhang N; Jiang Y; Zou J; Yu Q; Zhao W
Proteins; 2009 May; 75(3):671-81. PubMed ID: 19003984
[TBL] [Abstract][Full Text] [Related]
13. Role of phosphorylated Thr160 for the activation of the CDK2/Cyclin A complex.
De Vivo M; Cavalli A; Bottegoni G; Carloni P; Recanatini M
Proteins; 2006 Jan; 62(1):89-98. PubMed ID: 16292742
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.
Dessalew N; Bharatam PV
Eur J Med Chem; 2007 Jul; 42(7):1014-27. PubMed ID: 17335939
[TBL] [Abstract][Full Text] [Related]
15. Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors.
Vulpetti A; Casale E; Roletto F; Amici R; Villa M; Pevarello P
J Mol Graph Model; 2006 Mar; 24(5):341-8. PubMed ID: 16260160
[TBL] [Abstract][Full Text] [Related]
16. The design and synthesis of potent and selective inhibitors of Trypanosoma brucei glycogen synthase kinase 3 for the treatment of human african trypanosomiasis.
Urich R; Grimaldi R; Luksch T; Frearson JA; Brenk R; Wyatt PG
J Med Chem; 2014 Sep; 57(18):7536-49. PubMed ID: 25198388
[TBL] [Abstract][Full Text] [Related]
17. An analysis of the binding modes of ATP-competitive CDK2 inhibitors as revealed by X-ray structures of protein-inhibitor complexes.
Vulpetti A; Pevarello P
Curr Med Chem Anticancer Agents; 2005 Sep; 5(5):561-73. PubMed ID: 16178778
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of kinase inactivation and nonbinding of FRATide to GSK3β due to K85M mutation: molecular dynamics simulation and normal mode analysis.
Lu S; Jiang Y; Lv J; Zou J; Wu T
Biopolymers; 2011 Oct; 95(10):669-81. PubMed ID: 21442609
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a potential allosteric ligand binding site in CDK2.
Betzi S; Alam R; Martin M; Lubbers DJ; Han H; Jakkaraj SR; Georg GI; Schönbrunn E
ACS Chem Biol; 2011 May; 6(5):492-501. PubMed ID: 21291269
[TBL] [Abstract][Full Text] [Related]
20. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex.
Echalier A; Bettayeb K; Ferandin Y; Lozach O; Clément M; Valette A; Liger F; Marquet B; Morris JC; Endicott JA; Joseph B; Meijer L
J Med Chem; 2008 Feb; 51(4):737-51. PubMed ID: 18232649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]